Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
8Citations signalées
39Institutions associées
4Pays d’affiliation
Résumé indisponible dans les métadonnées reçues.
Institutions
Xijing HospitalAir Force Medical UniversitySheng Jing HospitalChina Medical UniversitySir Run Run Shaw HospitalZhejiang UniversityWuhan UniversitySun Yat-sen UniversitySixth Affiliated Hospital of Sun Yat-sen UniversityShanghai Jiao Tong UniversityRuijin HospitalLinkou Chang Gung Memorial HospitalSichuan UniversityWest China Hospital of Sichuan UniversityTang Du HospitalTianjin Medical University General HospitalCentral South UniversityXiangya Hospital Central South UniversityGuangzhou First People's HospitalGuangzhou Medical UniversityBeijing Luhe Hospital Affiliated to Capital Medical UniversityInje University Haeundae Paik HospitalFudan UniversityZhongshan HospitalThe First Affiliated Hospital, Sun Yat-sen UniversityArmy Medical UniversityDaping HospitalSoochow UniversityFirst Affiliated Hospital of Soochow UniversityPeking UniversityPeking University People's HospitalRenji HospitalShanghai East HospitalNingbo First HospitalWuxi People's HospitalChina Medical UniversityChina Medical University HospitalShanghai Hospital Development CenterEverest University
Sujets associés
Inflammatory Bowel DiseaseSphingolipid Metabolism and SignalingRheumatoid Arthritis Research and Therapies